Min menu


Latest News

The University of Oxford launches the world's first trial of combining the AstraZeneca and Pfizer vaccines for Corona

A report by the American agency "Bloomberg" revealed the launch of the first experiment in the world conducted by the University of Oxford that combines Corona virus vaccines from AstraZeneca and Pfizer, which could provide greater flexibility in the use of scarce supplies in the world.

According to the report, the university will begin recruiting 820 participants over the age of 50 across eight British sites this week, according to Thursday's statement, the Oxford and Pfizer vaccines will be given in a different order and in two dosing intervals, with an interval of four and 12 weeks.

The experience will allow researchers to see whether two doses of different vaccines produce better or worse results than two doses of the same product.The study can be key to relieving the pressure on individual vaccine makers to administer vaccines if they encounter manufacturing difficulties.

Delays in supplies from AstraZeneca and other pharmaceutical companies have led to tensions with the European Union, prompting the European Union to impose export controls to help boost its own vaccines. If the doses could be combined, countries might be more open to helping each other with surplus supplies.

Registration should be completed this month, with preliminary data expected around June, according to Matthew Snape, the Oxford investigator leading the trial, the UK government contributed 7 million pounds ($ 9.6 million) to the study.

Mixing vaccines to create an enhanced immune response is common with vaccines that target diseases such as hepatitis A and B, and the combined shots can enhance the immune response because the second shot will not be limited by any immunity the body has built for the first vaccine delivery platform.

The dose shots of the Oxford / AstraZeneca and Pfizer vaccines target the spike protein that the virus uses to enter cells, the British pharmaceutical company vaccine is carried by a weak chimpanzee adenovirus, while the American company Pfizer shot uses a genetic material called messenger RNA.

The study's organizers said that their trial is the first combined trial to start globally, although next week Russia will also start mixing AstraZeneca with Sputnik V in Azerbaijan and the United Arab Emirates.

The study will look at the side effects and the immune response produced by the combinations, but not their efficacy. This was tested in large trials required for clearance and was measured by the rate of infection.

Snap said in an interview that the study will be the first to test the Pfizer vaccine, which is usually given in two doses at a 21-day interval, with an interval of 12 weeks. The American company and the German partner Biontech have conducted clinical trials with doses three weeks apart, but UK health officials have extended The time interval to allow more people to get their first dose quickly.